IMTIB   27019
INSTITUTO DE MEDICINA TRASLACIONAL E INGENIERIA BIOMEDICA
Unidad Ejecutora - UE
artículos
Título:
Acquisition of stem associated-features on metastatic osteosarcoma cells and their functional effects on mesenchymal stem cells
Autor/es:
GUTIERREZ LUCIANA (1RA AUTORÍA COMPARTIDA); ALBERTO LAZAROWSKY; AUZMENDI JERONIMO; BOLONTRADE MARCELA; VALENZUELA MATIAS (1RA AUTORÍA COMPARTIDA); CORREA DOMINGUEZ ALEJANDRO
Revista:
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
Editorial:
ELSEVIER SCIENCE BV
Referencias:
Lugar: Amsterdam; Año: 2020 vol. 1864
ISSN:
0304-4165
Resumen:
Abstract: Background: Osteosarcoma (OS) is the most frequent malignant bone tumor, affecting predominantly children and young adults. Metastases are a major clinical challenge in OS. In this context, 20% of OS patients are diagnosed with metastatic OS, but near 80% of all OS patients could present no-detectable micrometastasis at the moment of diagnosis.Methods: Osteogenic differentiation; doxorubicin exclution assay;fluorescense microscopy; RT-qPCR; proteomic analysis.Results: Our results suggest that metastatic OS cells posses a diminished osteoblastic differentiation potential with a gain of metastatic traits like the capacity to modify intracellular localization of chemodrugs and higher levels of expression of stemness-related genes. On the opposite hand, non-metastatic OS cells posses bone-associated traits like higher osteoblastic differentiation and also an osteoblastic-inducer secretome.OS cells also differ in the nature of their interaction with mesenchymal stem cells (MSCs), with opposites impacts on MSCs phenotype and behavior.Conclusions: All this suggests that a major trait acquired by metastatic cells is a switch into a stem-like state that could favor its survival in the pulmonary niche, opening new possibilities for personalized chemotherapeutic schemes.General Significance: Our work provides new insights regarding differences among metastatic and non-metastatic OS cells, with particular emphasis on differentiation potential, multidrug resistance and interaction with MSCs.